Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT01987843 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: MT-1303-Low
DRUG: MT-1303-Middle
DRUG: MT-1303-High
DRUG: Placebo

Sponsor

Tanabe Pharma Corporation